The persistence of attention deficit hyperactivity disorder (ADHD) into adolescence and adulthood has now been accepted as a clinical entity. The rate of prevalence among adults is assumed to be from 2% to 4%. With increasing age, a symptom change has to be considered; disturbance of attention becomes more prominent, whereas hyperactivity often diminishes or changes to inactivity. Neuroimaging studies show a high striatal dopamine transporter (DAT) availability in most adults with ADHD; this can be reduced by stimulants. Nicotine seems to have a stimulant-like action on the DAT. In most adults with ADHD, therapy has to be multimodal, combining psychotherapy and medication. Methylphenidate is the first-line drug in adult ADHD; further options are amphetamine and noradrenaline reuptake inhibitors. Nonresponders to methylphenidate seem to have no elevated DAT availability prior to therapy. Combination with other psychiatric disorders occurs frequently in adults with ADHD; in these patients additional pharmacological treatment with special regard to the comorbid disease is recommended.
changes to inactivity; therefore, ADHD often is not accepted as a diagnosis in adults. Impulsivity normally lessens with age. Adults with ADHD seem to have a problem with willpower: activity can be overexerted, but if a task is not attractive to the person, this results in a lack of effort. Or, inattention can change to hyperfocussing, when the person is attracted by a task. With adults, differing patterns of comorbidity and symptom heterogeneity pose new conceptual, diagnostic, and treatment challenges. While core symptoms are often overt problems in children, in adults subtler executive dysfunction appears. Even though the growing consensus is that ADHD is a disorder of executive functions (EF), the details of the EF/ADHD connection remain unclear and may be far more complex in adults. 4 In Table I examples are given for the changes of the 18 DSM-IV symptoms from childhood to adulthood. The 6-question Adult Self-Report Scale -V 1.1 (ASRS -V 1.1) Screener (http://www.hcp.med.harvard.edu/ncs/fpdir/adhd) is a subset of the WHO's 18-question Adult Self-Report Scale -V 1.1 (ASRS -V 1.1) Symptom Checklist. The patient should fill in checkmarks. Four or more checkmarks in the darkly shaded areas may indicate that the symptoms are consistent with adult ADHD (Figure 1 ). Wender developed a set of characteristics to specify both childhood criteria and current ADHD symptoms. 5 He pointed out affective lability, which is not mentioned in DSM-IV, as a frequent symptom in adult ADHD.
Prevalence of ADHD in adulthood
The prevalence of ADHD in children according to DSM-IV criteria varies from 2.4% to 19.8%. 6 Concerning persistence into adulthood, most authors describe a rate of about 50%. The largest follow-up study, which investigated 197 Chinese children after 15 years, showed a rate of persistence of 70%. 7, 8 Generally, the degree of prevalence (1% to 6% in adults) depends on the view of the reporter in the initial assessment. Most instruments consist of some form of self-report, and in adulthood it is often not possible to ask information of parents or persons with a close relationship to the patient. Patients with ADHD are often not aware of their symptoms, or do not report the severity of symptoms.
Neurobiological basis of ADHD
Current interest in the neurobiological basis of ADHD originally commenced in the 1970s. Neurochemical, neurophysiological, and radiological attributes were noted, proving, in particular, abnormalities in the dopaminergic and noradrenergic system. Genetic investigations showed increased evidence that genetic components were present in most cases of ADHD, which is now seen as the psychiatric disease with the highest heritability. 9 Neuroimaging studies with magnetic resonance imaging (MRI), photon-emission tomography (PET), and single photon-emission computed tomography (SPECT) suggest involvement of striatal structures in ADHD. [10] [11] [12] [13] Molecular genetic studies described an involvement of a polymorphism of the dopamine transporter (DAT) 1 gene in ADHD (eg, a higher rate of homozygosity of the 10-repeat allele in the 3´untranslated region of exon 15 of the DAT gene on chromosome 5p15.3). [14] [15] [16] [17] [18] [19] With regard to the suspected striatal impairment in ADHD and the known effect of methylphenidate on the C l i n i c a l r e s e a r c h DAT mainly localized in this section of the brain, since the end of the 1990s DAT has been investigated in patients with ADHD. This is carried out by using radioactive marked ligands which are known to bind effectively with the DAT system. A group of investigators from Boston used altropane marked with iodine-123 20 ; our group from Munich and Philadelphia used the cocaine derivative TRODAT-1 marked with technetium 99m. 21 Both studies showed a clearly higher availability of DAT in the striatum of adult patients with ADHD compared with the normal healthy controls. [20] [21] [22] [23] While DAT availability was found to be raised to 17% in the investigations using TRODAT-1 compared with the control collective (Figure 2) , the group using altropane demonstrated a rise of 70% in 6 patients; Often does not follow through on instructions and fails to finish schoolwork, chores, or duties in the workplace (and due to oppositional behavior or failure to understand instructions) Often has difficulty organizing tasks and activities
Is often forgetful in daily activities
Often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort (such as schoolwork or homework) Often fidgets with hands or feet or squirms in seat Is often "on the go" or often acts as if "driven by a motor" Often fails to give close attention to details or makes careless mistakes in schoolwork, work, or other activities Often has difficulty sustaining attention in tasks or play activities Often does not seem to listen when spoken to directly Often loses things necessary for tasks or activities (eg, toys, school assignments, pencils, books, or tools) Is often easily distracted by extraneous stimuli Often leaves seat in classroom or in other situations in which remaining seated is expected Often runs about or climbs excessively in situations in which it is inappropriate (in adolescents or adults, may be limited to subjective feelings of restlessness) Often has difficulty playing or engaging in leisure activities quietly
Often talks excessively
Often blurts out answers before questions have been completed
Often has difficulty awaiting turn Often interrupts or intrudes on others (eg, butts into conversations or games) this percentage was reduced to around 30% in a larger group of 19 patients on continuation of the altropane study (Spencer T, personal communication) . Meanwhile, a rise in DAT availability was also detected in the basal ganglia of children with ADHD by means of an [
123 I] N-(3-iodopropen-2-yl)-2-carbo-methoxy-3β-(4-chlorphenyl) tropane (IPT)-SPECT investigation, 24 following initial results with N-ω-fluoropropyl-2 β-carboxymethoxy-3 β-{4-iodophenyl} tropane (FP-CIT). 25 Interestingly, a rise in the DAT could not be detected in a SPECT investigation with β-CIT
26
; this could be due to the extremely slow kinetics of β-CIT (measurement 1 day after application) or another specificity of this radiotracer, which also binds with serotonin transporters and possibly holds other substructures of DAT compared with altropane, FP-CIT, IPT, or TRO-DAT-1. Our own initial results revealed that the DAT was raised not only in the hyperactive-impulsive and combined type, but also in the inattentive type of ADHD (Figure 3 ). It may be deduced from a neurochemical view that with an increase in DAT, which transports dopamine back from the synaptic cleft, less dopamine is available in the synaptic cleft of dopamine-dependent neurons. The results obtained by our group showed not only the impairment of DAT but also reported for the first time in vivo and intraindividually in patients with ADHD, that impaired metabolism can be improved with methylphenidate: on administration of 5 mg 3 times daily it was seen that there was a clear reduction in DAT availability in all patients after a period of 4 weeks (Figure 2) . 22, 23 With this very low dose, most of these patients demonstrated a lower concentration of DAT than did the control group. In a study involving six children with ADHD, an IPT-SPECT investigation confirmed a marked reduction in DAT density under administration of methylphenidate. 27 Regarding normal healthy individuals, other authors were able to show evidence of a similar reduction in DAT under methylphenidate in a PET investigation with [C-11] cocaine. 28 In conclusion, the SPECT investigations on DAT confirmed the supposition that with ADHD an impairment is present mainly in the dopaminergic system. This can be improved with the introduction of stimulants. Our initial results show that nonresponders to methylphenidate do not reveal raised DAT in striatum prior to therapy, whereas the responders seem to have a high DAT availability (Figure 4 ). It should be noted, for possible diagnostic applications of SPECT, that the DAT concentration decreases with increase of age 30 and that nicotine may influence DAT availability. 12 The lowering of DAT with increasing age may be an explanation for our observation, that most adults need lower doses of methylphenidate compared with children and adolescents. Nicotine seems to have a similar effect on the DAT as do stimulants (Figure 3) . Investigating potential reasons for the lower elevation in the TRODAT-1 study compared with the altropane study, we found a subgroup of patients with relatively little increase in DAT despite severe clinical impairments; further questioning of these patients revealed that all of them were cigarette smokers. Comparison of 11 smoking nonmedicated patients with ADHD with sex-and agematched nonsmoking drug-naive adults with ADHD showed significantly higher DAT density in the nonsmoking patients, despite higher ADHD scores for the smokers. 31 This finding suggests that nicotine may act directly on DAT in the same manner as stimulants. In a self-trial, DAT availability was reduced by over 50% 5 hours after intake of 20 mg methylphenidate in a slow-release formulation; wearing a nicotine skin patch, equaling 10 to 20 cigarettes daily, for 5 hours. In the same subject 3 months later, an effect similar to that of methylphenidate was seen ( Figure  5 ), confirming the view that the lowering of DAT after use of nicotine is not a sign of a neurochemical adaptation associated with chronic exposure to nicotine. 12 Further evidence comes from the reevaluation of a woman with ADHD, who was smoking 15 cigarettes per day at the time 
Transversal
of first investigation with TRODAT-1, showing no remarkable elevation of DAT; 4 weeks of intake of 3x5 mg methylphenidate led to a marked reduction similar to the other patients in this group. One year later, the patient stopped the nicotine and methylphenidate intake; 2 years after the first investigation she returned with increased complaints of ADHD.At this time she underwent another TRODAT-1 SPECT scan, presenting with a 19% elevation compared with the first scan with nicotine and a 61% elevation compared with the second scan with nicotine and methylphenidate ( Figure 6 ). This finding is in accordance with the opinion that the effect of nicotine on DAT does not result in a persistent loss of DAT. 32 In this context, it is of interest that an investigation with [
123 I]β-CIT SPECT showed no altered striatal uptake in smokers versus controls, 33 a potential parallel to the above mentioned findings of no DAT elevation in ADHD with this method.
Treatment of adults
Most patients need multimodal therapy: psychoeducation concerning the special aspects of ADHD is essential. Many patients have problems with their self-esteem due to a misunderstanding of the symptoms and a childhood with parents suffering from ADHD-especially impulsivity-and they need additional psychotherapy. Treatment with stimulants is the drug therapy of first choice 34 and is approved in the USA for adults (dmethylphenidate and amphetamines); stimulants for adult ADHD are as effective as in children. An investigation performed in the year 2000 in Germany showed that only 0.024‰ of the adults registered in the public health system-that is 90% of the adult population-was treated with methylphenidate in Germany at this time (Figure 7) . 35 That is about one out of 40 000 and includes all kinds of treatments, including for narcolepsy and other psychiatric diseases. In the treatment of adults with ADHD we start with a daily dose of 5 mg, reaching 15 mg methylphenidate after 14 days of treatment. Titration up to 40 mg follows, if the patient needs more than the initial end point of the 15-mg dose. But more than 70% of our patients did not tolerate doses above 30 mg without having marked side effects. Frequently, they felt an increased inner tension. With higher doses, they also described a state resembling the impairments they experienced before the treatment. Most of them had a good stabilization with a combination of methylphenidate in a dose up to 20 mg and additional antidepressants. With all patients we try to start monotherapy with stimulants. When methylphenidate has no positive effect on depressive or other comorbid symptoms, we start an additional medication after 4 weeks of treatment. Some patients do not tolerate methylphenidate well; they feel more depressed after starting the methylphenidate medication, but they are not as inattentive as before the beginning of therapy; in this situation we change from methylphenidate to amphetamines; some patients have more benefits from this kind of stimulants acting in dual ways.When selecting the additional medication it is important to regard the comorbid disorder. We experienced good clinical response with the following medication: The use of tricyclic antidepressants is problematic, as the long-term effect is not as good as that of treatment with new antidepressants.The change seems to take place after 3 months.The side effects often lead to treatment dropouts. In recent years the norepinephrine reuptake inhibitor atomoxetine was introduced as an additional possibility to treat ADHD. 36 This substance does not influence the dopamine in the striatum, but in the prefrontal cortex, where dopamine transport is mediated by norepinephrine transporter. 
